You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR PLEGRIDY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PLEGRIDY

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00906399 ↗ Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis Completed Biogen Phase 3 2009-06-01 The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.
NCT01332019 ↗ Long-Term Safety and Efficacy Study of Peginterferon Beta-1a Completed Biogen Phase 3 2011-04-01 The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
NCT01911767 ↗ Biogen Multiple Sclerosis Pregnancy Exposure Registry Recruiting Biogen 2013-10-30 The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study is to prospectively evaluate pregnancy outcomes in women with MS who were unexposed to disease-modifying therapies (DMTs).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PLEGRIDY

Condition Name

Condition Name for PLEGRIDY
Intervention Trials
Multiple Sclerosis 4
Relapsing Multiple Sclerosis 3
Multiple Sclerosis, Relapsing-Remitting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PLEGRIDY
Intervention Trials
Multiple Sclerosis 13
Sclerosis 10
Multiple Sclerosis, Relapsing-Remitting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PLEGRIDY

Trials by Country

Trials by Country for PLEGRIDY
Location Trials
United States 86
India 21
Germany 20
France 20
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PLEGRIDY
Location Trials
North Carolina 7
Kentucky 4
Georgia 4
Ohio 4
Tennessee 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PLEGRIDY

Clinical Trial Phase

Clinical Trial Phase for PLEGRIDY
Clinical Trial Phase Trials
Phase 4 5
Phase 3 5
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PLEGRIDY
Clinical Trial Phase Trials
Completed 6
Recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PLEGRIDY

Sponsor Name

Sponsor Name for PLEGRIDY
Sponsor Trials
Biogen 12
New York University School of Medicine 1
NYU Langone Health 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PLEGRIDY
Sponsor Trials
Industry 12
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.